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P2Y12 or P2Y1 Inhibitors Reduce Platelet Deposition in a Microfluidic
Model of Thrombosis while Apyrase Lacks Efficacy Under Flow
Conditions
Abstract
Determination of the patient-specific response to antiplatelet agents facilitates proper dosing for both acute
and chronic prophylaxis. "Closed" systems (with or without flow) may fail to predict pharmacological potency
in situations where platelets rapidly accumulate under flow conditions at the site of thrombosis ("Open"
systems). Using an 8-channel microfluidic flow assay of human whole blood with corn trypsin inhibitor (±
PPACK) perfused over focul zones of collagen, dose-response curves were measured for pharmacological
agents at a wall shear rate of 210 s-1. The P2Y1 inhibitor MRS 2179 (IC50 = 0.233 ± 0.132 µM) and P2Y12
inhibitor 2-MeSAMP (IC50 = 2.558 ± 0.799 µM) were potent blockers of secondary platelet accumulation
under flow, while the P2X1 inhibitor (NF 449) and apyrase failed to reduce platelet accumulation. MRS 2179
and 2-MeSAMP and undetectable effects on initial platelet adhesion to collagen. Numerical simulation of
convective-diffusive transport and apyrase-mediated catalytic degradation of ADP indicated that ultra-high
concentrations of apyrase (~ 2000 U mL-1) would be required to have the same effect under flow as much
lower concentrations (1 U mL-1) currently used in closed systems (aggregometry or cone-and-plate
viscometer). This is the first evaluation of IC50 values for P2Y12 and P2Y1 antagonists under controlled flow
conditions. Evaluation of antiplatelet agents in open flow systems demonstrates that inhibition of either ADP
by apyrase or antagonism of P2X1 signaling had no inhibitory effect on platelet accumulation. This technique
provides a platform for rapidly investigating effects of antithrombotic therapies simultaneously in a model
injury system.
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P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microﬂuidic
model of thrombosis while apyrase lacks eﬃcacy under ﬂow conditionsw
S. F. Maloney,a Lawrence F. Brassb and S. L. Diamond*a
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First published as an Advance Article on the web 5th January 2010
DOI: 10.1039/b919728a
Determination of the patient-speciﬁc response to antiplatelet agents facilitates proper dosing for
both acute and chronic prophylaxis. ‘‘Closed’’ systems (with or without ﬂow) may fail to predict
pharmacological potency in situations where platelets rapidly accumulate under ﬂow conditions at
a site of thrombosis (‘‘Open’’ systems). Using an 8-channel microﬂuidic ﬂow assay of human
whole blood with corn trypsin inhibitor ( PPACK) perfused over focal zones of collagen,
dose-response curves were measured for pharmacological agents at a wall shear rate of 210 s1.
The P2Y1 inhibitor MRS 2179 (IC50 = 0.233  0.132 mM) and P2Y12 inhibitor 2-MeSAMP
(IC50 = 2.558  0.799 mM) were potent blockers of secondary platelet accumulation under ﬂow,
while the P2X1 inhibitor (NF 449) and apyrase failed to reduce platelet accumulation. MRS 2179
and 2-MeSAMP had undetectable eﬀects on initial platelet adhesion to collagen. Numerical
simulation of convective-diﬀusive transport and apyrase-mediated catalytic degradation of ADP
indicated that ultra-high concentrations of apyrase (B2000 U mL1) would be required to have
the same eﬀect under ﬂow as much lower concentrations (1 U mL1) currently used in closed
systems (aggregometry or cone-and-plate viscometer). This is the ﬁrst evaluation of IC50 values
for P2Y12 and P2Y1 antagonists under controlled ﬂow conditions. Evaluation of antiplatelet
agents in open ﬂow systems demonstrates that inhibition of either ADP by apyrase or antagonism
of P2X1 signaling had no inhibitory eﬀect on platelet accumulation. This technique provides a
platform for rapidly investigating eﬀects of antithrombotic therapies simultaneously in a model
injury system.
Introduction
Antiplatelet therapies can prevent excessive clotting in patients
with a wide range of pathologies.1,2 Targeting the thromboxane
A2 pathway with aspirin
3 or ADP feedback via the P2-family
of platelet receptors4,5 reduces secondary platelet activation
pathways6 and reduces pathologically excessive clot formation
while not interfering with primary platelet adhesion and
activation necessary for general hemostasis. However, bleed-
ing risks and variability of patient response to antiplatelet
therapies often mandate careful monitoring of patients. For
example, a signiﬁcant number of patients fail to respond to
antiplatelet drugs, clopidogrel in particular.7
The most popular current target of antiplatelet therapy is
the G protein-coupled receptor P2Y12, which is one of the
three P2-family proteins found on the platelet surface.8 The
receptor is activated by the binding of its ligand, ADP,
released from activated platelets at the site of injury, which
in turn causes activation of Gi2, inhibition of adenylyl cyclase
and activation of PI3 kinase, a rise of cytosolic calcium,
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Insight, innovation, integration
Blood hemostasis and thrombosis are complex processes
that occur in the presence of ﬂow. The assembly of platelet
aggregates and their pharmacological antagonism may be
dependent on whether the assay system is open or closed
and whether hemodynamic ﬂow is present. Protein micro-
patterning and microﬂuidic devices provide the ideal
setting to recreate focal thrombotic events and measure
the potency of antiplatelet agents in the presence of ﬂow.
With such a device to image 8 simultaneous clotting
events, platelet antagonists that targeted the P2Y1 or
P2Y12 receptors resulted in dose-dependent inhibition of
thrombosis, while apyrase (a potent inhibitor in closed
systems) had no activity under ﬂow. Numerical convection-
diﬀusion-reaction simulations revealed the kinetic limita-
tions where apyrase may increase thrombosis in some
conditions.
This journal is c The Royal Society of Chemistry 2010 Integr. Biol., 2010, 2, 183–192 | 183
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and ﬁnally granule release and shape change.9 P2Y1 is the
second G protein-coupled receptor that has been targeted as
an antiplatelet therapeutic target. Binding of ADP to this
other receptor on the platelet surface, which is Gq coupled,
10
leads to phospholipase b (PLCb) activation and subsequent
platelet activation. The third P2-family receptor, the P2X1
receptor, is an ATP ligand-gated ion channel,11 which directly
leads to the inﬂux of calcium from the extracellular milieu. The
role of platelet P2X1 signaling is less well deﬁned with respect
to platelet activation and thrombus formation.12,13 Finally,
the enzyme apyrase (ATP-diphosphohydrolase, EC 3.6.1.5)
which actively hydrolyzes ATP to ADP and ADP to the
hemostatically irrelevant AMP is used commonly in aggrego-
metry, cone-and-plate viscometry, and other in vitro experi-
mental techniques to remove the ligands of the P2 family
receptors from the bulk solution. Endogenous ATP- and
ADPases exist throughout the vaculature (CD39) to keep
circulating concentrations below activating levels. The thera-
peutic potentials of recombinant apyrase14 or solubilized
CD3915 are currently being explored as potential antiplatelet
therapies.
Evaluation of platelet function and pharmacological agents
can occur in closed systems of constant volume that lack ﬂow
(e.g. intracellular calcium measurement, automated calibrated
thrombography) or include ﬂow (e.g. aggregometry or cone-
and-plate viscometry). However, these laboratory approaches
fail to recreate the fact that intravascular thrombosis is an open
system where blood is continually ﬂowing over a thrombotic
site. In open systems, the rapid accumulation of platelets at a
surface leads to platelet concentrations greatly exceeding those
found in whole blood and the delivery/removal of species
by convection may impact the eﬃcacy of pharmacological
agents. Various in vitro ﬂow systems allow precise control
of hemodynamics, surface characteristics, and inlet blood
pharmacology.16–22 If a pharmacological agent is potent in a
closed system but lacks eﬃcacy in an open system, then the
therapeutic beneﬁt of the agent may be limited with respect
to reducing intravascular thrombosis under ﬂow. This work
explores the eﬃcacy of one enzymatic and three pharma-
cological platelet activation inhibitors, showing that receptor
antagonism is eﬀective even in open ﬂow systems, whereas
enzymatic intervention can be ineﬀective or even detrimental
to preventing platelet activation.
Experimental
Materials and methods
Blood collection and labeling. Blood was obtained from
healthy individuals who had refrained from taking medica-
tions for at least ten days prior to donation. Informed consent
was obtained for each volunteer and performed in accordance
with IRB approval from the University of Pennsylvania’s
Oﬃce of Regulatory Aﬀairs and the Declaration of Helsinki.
Whole blood was drawn via venipuncture into corn trypsin
inhibitor (CTI, Haematologic Technologies Inc., Essex Junction,
VT, USA) to a ﬁnal concentration of 50 mg mL1 to inhibit
Factor XIIa. Aliquots of 200 mL whole blood were labeled
with 4 mL of AlexaFluor 647 conjugated anti-CD41 (aIIb)
antibody (Clone PM6/248, AbD Serotec, Raleigh, NC, USA),
which had no eﬀect on platelet function (results not shown).
In order to inhibit thrombin function in some experiments,
H-D-Phe-Pro-Arg-chloromethylketone (PPACK, Calbiochem,
San Diego, CA, USA) was added to a ﬁnal concentration of
100 mM. CTI-treated whole blood was perfused through the
ﬂuidic chamber within 15 min of phlebotomy.
Microﬂuidic fabrication and protein patterning. Microﬂuidic
devices were fabricated in poly(dimethylsiloxane) (PDMS,
Sylgard 184, Ellsworth Adhesives, Germantown, WI, USA)
using well established techniques.23 Detailed fabrication methods
and patterning techniques were performed similarly to previously
published methods,19 with device design and a sample device
shown in Fig. 1. Brieﬂy, glass slides (75 mm  50 mm  1 mm,
Fisherbrand, Fisher Scientiﬁc, Pittsburgh, PA, USA) were
cleaned and functionalized with Sigmacote (Sigma-Aldrich,
St. Louis, MO, USA) to form a hydrophobic surface to
aid collagen adsorption. Human Type-I collagen (Vitrocol
3.0 mg mL1, Advanced BioMatrix, San Diego, CA, USA)
was diluted to 300 mg mL1 in HEPES buﬀered saline (HBS,
20 mM N-(2-hydroxyethyl)piperazine-N0-2-ethanesulfonic
acid, 150 mM NaCl, pH 7.4) with 10 mL 0.1 M sodium
hydroxide solution to neutralize pH to 7.0 to a ﬁnal volume
of 1 mL. Microﬂuidic devices were then ﬁlled with the solution
and allowed to incubate at room temperature for 150 min to
polymerize the collagen into a thin ﬁlm on the surface of the
slide. Excess solution was removed, immediately followed by
placement of the ﬂow device aligned on the formed collagen
region. A solution of 0.5% bovine serum albumin (BSA) in
HBS was then ﬁlled through the channels and allowed to sit at
room temperature for at least 60 min in order to prevent non-
speciﬁc platelet binding to both the PDMS and the un-reacted
glass surface.
Flow cytometry and device characterization. Fluorescent
particles (FTIC and PE-Cy5 Easy Calibration Kits, Sphero-
tech, Lake Forest, IL, USA) were diluted 1 : 9 (v : v) in 0.5%
BSA in HBS to a particle concentration of approximately
2 105 particles mL1. Control mixtures of 10 mL of each type
of ﬂuorescent particle (FITC Peaks 2,3,4, and 5 and PE-Cy5
Peaks 2,3,4, and 5) were mixed in a microcentrifuge tube.
Particles were assigned to input positions on the ﬂow device
using a random number generator and perfused through the
device using a gastight syringe (250 mL, Hamilton Company,
Fig. 1 Multiple-inlet single outlet ﬂow device used for IC50-on-a-chip
experiments. (A) Schematic of microﬂuidic ﬂow device used to investigate
the eﬀect of eight diﬀerent inhibitor concentrations on platelet aggregate
formation simultaneously. (B) Photograph of actual device used. Physical
device dimensions are 4.5  2 inches.
184 | Integr. Biol., 2010, 2, 183–192 This journal is c The Royal Society of Chemistry 2010
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Reno, NV, USA) mounted on a syringe pump (PHD 2000,
Harvard Apparatus, Holliston, MA, USA) at a volumetric
ﬂow rate of 16 mL min1 for 5 min. The eﬄuent was collected
in Tygon tubing (0.020 inch ID, 0.060 inch OD, Fisher
Scientiﬁc, Pittsburg, PA, USA) and subsequently infused
into a microcentrifuge tube for assaying. Flow cytometry was
performed on an Accuri A6 ﬂow cytometer (Accuri Cytometers
Inc., Ann Arbor, MI, USA) ﬁtted with the CSampler auto-
mated plate sampler. Gates were applied in CFlow Plus soft-
ware and kept constant across all samples analyzed.
Inhibitor preparation. 20-Deoxy-N6-methyl adenosine 30,50-
diphosphate (MRS 2179), Grade VIII apyrase from potato
(Solanum tuberosum), 2-methylthioadenosine 5-monophosphate
(2-MeSAMP) (Sigma Aldrich, St. Louis, MO, USA), and
4,40,40 0,40 0 0-[carbonylbis(imino-5,1,3-benzenetriyl-bis(carbonyl-
imino))]tetrakis-1,3-benzenedisulfonic acid (NF 449, Tocris
Bioscience, Ellsiville, MO, USA) were dissolved in HBS to
working concentrations. Dilutions of compounds were made
to ten fold the desired ﬁnal concentration in HBS on the day of
the experiment, after which the inhibitor was added at a ratio
of 1 : 9 to ﬂuorescently labeled whole blood and allowed to
incubate for 5 min at room temperature, with gentle mixing at
2 min, except for apyrase which was added immediately prior
to perfusion. Final inhibitor concentrations used were: MRS
2179 (0–10 mM), 2-MeSAMP (0–200 mM), NF 449 (0–10 mM)
and apyrase (0–100 U mL1).
Platelet accumulation measurement. Blood samples incubated
with the given inhibitors were introduced to the inlet of the ﬂow
device and immediately perfused through the device at a
controlled volumetric ﬂow rate of 15 mL min1 for an average
wall shear rate at the collagen patch of 210 s1 (for rectangular
channels of cross sectional dimensions of 60 mm  250 mm).
Assembled devices were mounted on an inverted microscope
(IX81, Olympus America Inc., Center Valley, PA, USA) and
imaged using a CCD camera (ORCA-ER, Hamamatsu, Bridge-
water, NJ, USA) illuminated with a mercury lamp (100 W,
620 nm Ex/700 nm Em). Fields of view were captured using a
2 objective, integrating for 1000 ms, every 5 s for 5 min.
IC50 calculation. The far left and far right collagen regions
were identiﬁed by hand, with intermediate and corresponding
background regions interpolated using a custom MATLAB
script (MathWorks, Natick, MA, USA). Background-corrected
ﬂuorescence values were ﬁt using a four parameter logistical
model (eqn (1)):
FI ¼ Aþ A B
1þ ðI=CÞD ð1Þ
with ‘I’ representing the inhibitor concentration, ‘FI’ the back-
ground corrected ﬂuorescence of the corresponding region, ‘A’
and ‘B’ the minimum and maximum intensities, respectively,
and ‘C’ and ‘D’ the ﬁt parameters. The data were ﬁt using a
least-squares non-linear curve ﬁtting routine (MATLAB, Data
Analysis Toolbox).
Computational model of apyrase activity in open and closed
systems. In order to investigate the eﬀect of convective mass
transport on the hydrolysis of ADP and ATP by apyrase, a
set of ﬁnite element method numerical simulations were
performed. A commercial software package (COMSOLMulti-
physics, Burlington, MA, USA) was used to solve both the
steady-state ﬂow proﬁle and the coupled convection-diﬀusion-
reaction system in a 2-dimensional domain approximating the
2 mm surrounding a 250 mm reactive zone with a height of
60 mm. The hydrolysis of ADP by apyrase was approximated
by classical Michaelis–Menten kinetics using the published Km
for apyrase with ADP and ATP.24 The inﬂux of ADP and
ATP at the reactive surface was set to an experimentally
determined rate corresponding to full platelet activation25
which is comparable to previously estimated values,26,27 and
a value calculated from the platelet ﬂux to a collagen surface at
the given shear rate28 and the approximate ADP concentration
per platelet.29 Parameter values and boundary conditions are
shown in Table 1. Grid independence was performed by
evaluating the near-wall average concentration for a series of
increasingly reﬁned grids consisting of 13 840, 55 360, 105 429,
and 221 440 triangular elements, each with less than 0.001%
error from the estimate of the zero grid spacing solution using
Richardson extrapolation.30 The intermediate grid (105 429
elements) was used in order to optimize solution time and
accuracy. Steady-state momentum and mass balance calcu-
lations were performed using a direct solver (UMFPACK) on
a workstation (dual 2.2 GHz processors, 12 GB RAM).
The competition between ADP and ATP for hydrolysis by
apyrase was modeled using classical Michaelis–Menten
kinetics operating under the fast equilibrium assumption,
shown by eqn (2), solved algebraically in eqn (3):
ATPþ apyrase !Km1 ATP  apyrase !k1 ADPþ apyrase
ADPþ apyrase !Km2 ADP  apyrase !k2 AMPþ apyrase
ð2Þ
BATP ¼
ATP  Tapyrase 1 ADPKm2þADP
 
Km1 þATP ATPADPKm2þADP
BADP ¼ ADP  Tapyrase
Km2 þADP 1
ATP 1 ADP
Km2þADP
 
Km1 þATP ATPADPKm2þADP
2
4
3
5
ð3Þ
In order to approximate the instantaneous ADP concen-
tration in an aggregometry cuvette as a function of apyrase
concentration, the same reactive system outlined in eqn (2) was
used with a generation term to approximate ADP release from
platelets in a well-mixed control volume shown in eqn (4):
_mADP ¼
3
t
ﬃﬃﬃﬃ
2p
p exp 9ðttÞ
2
2t2
 
 TADP
0; t42t
8<
: 0ot  2t ð4Þ
which describes a normal distribution for ADP release to
a cumulative total of ‘TADP’, with a time of maximal instan-
taneous release ‘t’. The total ADP in the system was estimated
by the typical volume and platelet count in an aggregometry
cuvette (0.5 mL cuvette, 2  108 platelets mL1) with the same
approximate ADP concentration per platelet used in the open
system,29 with the maximal release time estimated from the
This journal is c The Royal Society of Chemistry 2010 Integr. Biol., 2010, 2, 183–192 | 185
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maximal rate of ADP release31,32 at 30 s, leading to a maximal
ADP concentration of 6 mM in the absence of degradation.
Statistical analysis. Data were compared to appropriate
controls using the Mann–Whitney U-test with p-values less
than 0.01 considered statistically signiﬁcant. All data are
plotted as the mean  standard deviation. All calculations
were performed using the MATLAB Statistics Toolbox.
Results and discussion
Device characterization
To verify equal ﬂow rates in each of the eight channels, each
inlet reservoir was spiked with a unique bead tracer that was
quantiﬁable by ﬂow cytometry (Fig. 2A). By measuring each
tracer bead concentration in the combined exit stream of the
microﬂuidic device (total ﬂow = 16 mL min1 for 5 min;
channel wall shear rate = 222 s1), the ﬂow rates were veriﬁed
to be equal across the chambers (Fig. 2B). This uniformity
across the channels was validated in 15 diﬀerent experiments
using 5 diﬀerent devices, thus conﬁrming the designed
intent that each reactive interaction zone is under statistically
indistinguishable hemodynamics and transport conditions.
Since thrombus buildup reached heights of o20% of the
chamber height for such short distances, the pressure drop
across an individual B250 mm long thrombus would be small
compared to the pressure drop across the entire length of a
channel. Thus, platelet accumulation at the collagen patch has
a minimal eﬀect on the ﬂow distributions within the system.
IC50 for platelet GPCR inhibitors during thrombosis under ﬂow
Three speciﬁc P2-family antagonists and apyrase were tested
in a dose-response mode to calculate eﬀective IC50 values for
collagen-induced platelet aggregate formation inhibition, in
the presence and absence of thrombin generation capability. In
each experiment, a total of eight simultaneously forming
thrombi were imaged in real-time (Fig. 3, and ESIw Fig. S1
and S4). Fluorescently labeled platelets accumulate only at the
site of collagen exposure, with minimal non-speciﬁc upstream
or downstream adhesion. The collagen displays substantial
surface coverage due to platelet adhesion to collagen within
1 min and subsequent secondary platelet accumulation via
platelet–platelet interactions over the 5 min experiment (ESIw
Fig. S1). Determination of total surface ﬂuorescence at 5 min
allowed a determination of the IC50 for each pharmacological
agent (Fig. 4, Table 2).
The P2Y1 and P2Y12 inhibitors displayed remarkably robust
dose-dependent reduction of platelets at a localized collagen
region. This was in contrast to the P2X1 inhibitor which had
no eﬀect, as has been demonstrated previously at comparable
shear rates in the lower physiological regime.33 The thrombin
generation at 5 min in this system with CTI appears to be
minimal, since there is no diﬀerence in the presence or absence
of an irreversible thrombin inhibitor. While the presence and
role of blood derived tissue factor exposed on or accumulating
at collagen-induced platelet activation is still under intense
investigation, the relatively short experimental time (5 min)
without exogenous tissue factor results in minimal thrombin
and ﬁbrin generation in this model system as expected.34
In contrast to small molecule P2-receptor antagonists,
apyrase operates by a diﬀerent mechanism in preventing
platelet activation by nucleotide substrates by enzymatic
hydrolysis. In the microﬂuidic focal model, apyrase was unable
to prevent collagen-initiated platelet accumulation, even at
extremely high levels (100 U mL1) of the enzyme. Incubating
the blood sample with apyrase for up to 10 min prior to
perfusion did not increase activity (results not shown). Enzyme
activity was conﬁrmed by reduction of ATP-mediated luciferase
signal (ESIw Fig. S2). The slight enhancement of platelet
deposition at >10 U mL1 may be due to conversion of
released ATP to ADP compared to the kinetically slower
reaction and weaker binding of ADP to apyrase compared
to ATP.
Numerical simulation of apyrase-mediated ADP hydrolysis
in open and closed systems
The closed system of an aggregometry cuvette was modeled
using eqn (2) and (3), with the instantaneous ADP concen-
tration at 2 min used to determine dose dependence, shown in
Fig. 5A. In order to approximate the amelioration of the
‘active cloud’35 of ADP generated at the site of platelet
activation by apyrase, average ADP concentrations in a region
5 mm above the length of the reactive zone were calculated
using a ﬁnite element method coupled to a convective ﬂow
Table 1 Physical parameters and boundary conditions used in numerical simulations
Parameter Value Reference
Density of whole blood 1.06  103 kg m3 (25 1C) 24
Viscosity of whole blood 4.7  103 Pa s (25 1C) 24
Diﬀusivity of ADP and ATP 1.14  1010 m2 s1 a
Flux of ADP (JADP) 4.4  106 and 7.8  1010 mol m2 s1 22, 33
Flux of ATP (JATP) 2/3  JADP 26
vx,max 4.18  103 m s1 b
Km, ADP 0.25 mol m
3 21
Km, ATP 0.06 mol m
3 21
kADP 100 mmol min
1 mg1 21
kATP 1210 mmol min
1 mg1 21
Subdomain conditions: ADP:r(DADPrcADP) = kATPBATP  kADPBADP  vx(y)rcADP. ATP: r(DATPrcATP) = kATPBATP  vx(y)rcADP.
Boundary conditions: ADP and ATP: Inlet: c = 0, Reactive surface: Flux = J, Outlet: Jout = vx(y)c (x = L,y), Walls and center line: rc = 0.
a Calculated from the Wilkie-Chang correlation for molecular diﬀusivity.48 b Determined by calculating the maximum velocity for a rectangular
duct with cross sectional dimensions of 250 mm  60 mm with a volumetric ﬂow rate of 1.88 mL min1.
186 | Integr. Biol., 2010, 2, 183–192 This journal is c The Royal Society of Chemistry 2010
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ﬁeld. These calculations were made across a range of apyrase
concentrations from 1  105 to 3  104 U mL1, with
representative samples shown in Fig. 5B. The steady-state
concentrations in the reactive zone were plotted as a function
of bulk apyrase concentration, calculating an eﬀective IC50
using eqn (1), with the dose response shown in Fig. 5C. As
shown in Fig. 5C, increasing the apyrase concentration eﬀec-
tively abolished any ADP in the closed system at 1 U mL1,
the concentration which is most commonly used in aggregometry.
The slight but reproducible increase in platelet accumula-
tion under high (10, 30 and 100 U mL1) apyrase concen-
trations, shown in Fig. 4G and H (ESIw Fig. S4G and S4H),
was hypothesized to be the result of preferential conversion of
ATP to ADP by apyrase at the location of the growing
thrombus. There are two prevalent isozymes of the apyrase
enzyme, with relative ATPase :ADPase activity ratios of 12 : 1
and 1 : 1,36 with most apyrase reagents supplied as mixtures of
the two. By running the numerical simulations with both pairs
of binding and kinetic rate parameters, it was possible to show
that in both the closed and open systems, an apyrase-mediated
increase in ADP is generated due to preferential conversion of
ATP released simultaneously during platelet degranulation as
shown in Fig. 5C. The dose-dependent behaviors were not
sensitive to the value of the surface ﬂux used in the open
simulation, which is important since literature estimates
for the eﬀective ADP ﬂux from a growing thrombus vary
over four orders of magnitude,25,28 indicating that the pheno-
mena is independent of the actual ADP ﬂux at the surface
(ESIw Fig. S3).
The 8-channel microﬂuidic focal injury model allows the
rapid determination of the eﬀective concentration of anti-
platelet and antithrombotic agents under ﬂow conditions. By
designing and fabricating a pair of microﬂuidic devices for
patterning collagen and for perfusion with tight spatial
control, this system is able to measure the accumulation
of ﬂuorescent platelets at 8 independent sites of collagen
exposure simultaneously. By dosing small volumes (90 mL)
of whole blood from a single donor with correspondingly
small volumes (10 mL) of inhibitor for each ﬂow channel, it
is possible to generate a full dose response curve from a single
experiment. The dose response behavior observed in this
system for both 2-MeSAMP and MRS 2179 was similar to
previously reported data using turkey erythrocyte inositol
phosphate accumulation (MRS 2179 IC50 = 0.330 mM),
37
human platelet ADP-induced calcium signaling depletion
(MRS 2179 IC50 = 0.260 mM),
38 and human platelet ADP-
induced aggregation prevention (2-MeSAMP IC50B 5 mM).
39
The biochemical modes of action of the P2Y1 and P2Y12
inhibitors used in this work are diﬀerent from the family of
compounds currently used to inhibit the receptors as anti-
platelet therapeutics (the thienopyridines). Such compounds
require metabolism to turn the administered pro-drug into the
active compound, which then binds its target receptor irrever-
sibly and prevents ligand binding and subsequent G protein
signaling. This mode of action is in contrast to the reversible
binding, direct acting compounds used in this work (MRS
2179 and 2-MeSAMP) or next generation therapies under
investigation (ARC69931MX). The reversibility of the com-
pound interaction with the receptor may be a concern, as
shown by a lack of eﬃcacy leading to the early termination of
the ARC69931MX trial (ClinicalTrials.gov identiﬁer
NCT00305162). However, the activity of MRS 2179 (IC50 B
200 nM) in this system was comparable to the published Ki of
138 nM.38 2-MeSAMP required a concentration approxi-
mately 10-fold higher than its calculated Kd (0.23 mM)
40 for
a half-maximal eﬀect in this assay (IC50 B 2.5 mM).
The inability of apyrase to prevent platelet accumulation at
a collagen surface and the corresponding numerical simulations
of both open and closed systems have several signiﬁcant
implications. The mode of action of an enzymatic degradation
of receptor ligand in the bulk phase is fundamentally distinct
from direct receptor antagonism. By preincubation of the
small molecule inhibitors with the blood sample, ample time
is given for diﬀusion to, recognition of, and equilibration with
Fig. 2 Characterization of the multiple inlet single outlet device conﬁrms equal ﬂow through each channel. (A) Flow cytometry data indicating the
clear identiﬁcations of eight distinct peaks in a single sample of eight volumetrically matched standards. Apparent scatter of each population is due
to the variability in the background signal of the non-ﬂuorescent channel. (B) Comparison of relative percent of particles in the eﬄux of the ﬂow
device from 15 experiments using 5 diﬀerent devices (bars are standard deviation, p > 0.05 for all compared to control).
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the antagonist’s given receptor, thereby disabling the ability of
the receptor to bind its ligand and signal. However, enzymatic
degradation of ligand must occur in the time between ligand
exposure, in this case ADP release from dense granules upon
primary platelet activation, and receptor binding. In closed,
well mixed systems, such as aggregometry cuvettes, the ligand,
enzyme, and receptor are all equally distributed throughout
the control volume. Under ﬂow conditions where platelets
accumulate to levels that are 10 to 50-fold greater than in
normal whole blood, apyrase is kinetically unable to decrease
local ADP concentrations. The experiments and simulations
were performed at relatively low (210 s1) shear rates com-
pared to the arterial vasculature, however convection is
still the dominant mode of ADP transport compared to
diﬀusion (Pe´clet number, Pe ¼ vLD ¼ 4900, convection dominant).
Additionally, a majority of the initial biochemical and platelet
function experiments are performed in plasma systems or with
washed platelets that may remove or reduce the activity of
endogenous ectopyrase enzymes, artiﬁcially increasing the
apparent eﬀectiveness of exogenous apyrase activity.
Upon further investigation of the preferential hydrolysis of
ATP to ADP for a speciﬁc isozyme of apyrase, it was
determined that local ADP concentrations, in the presence
of certain concentrations of apyrase, could actually be higher
than in the absence of apyrase. As shown in Fig. 6, even an
apyrase with equal kinetic parameters for both ATP and ADP
would not be able to have an eﬀect in an open system until
very high concentrations. The system modeled here only takes
into account the species released from platelets accumulating
and activating at a collagen patch. It is well established that
red blood cells are key factors in regulating vascular tone,
using ATP as one of the main mediators.41 Red cells can
release very signiﬁcant amounts of ATP, especially in hypoxic
conditions. Upwards of 2  107 molecules of ATP can be
released per cell, leading to local ATP concentrations of over
160 mM in a normal hematocrit with approximately 4.8  1012
red cells per L. In this regard, red blood cells act as sources of
ATP, which in the presence of circulating apyrase, could
lead to increased ADP concentrations at growing thrombi,
especially as surrounding tissues become oxygen starved
during occlusive events such as heart attacks and ischemic
strokes. This analysis implies that dosing high concentrations
of adenosine phosphatases required to have an eﬀect under
ﬂow conditions could actually increase platelet accumulation
at the site of injury which was observed in this model system
(at apyrase concentrations of 10, 30, and 100 U mL1), putting
individuals at risk for atherothrombosis at higher risk for
pathological clot formation. Interestingly, apyrase can block
shear-induced platelet activation (SIPA) detected at wall shear
rates greater than 5000 s1 in viscometers,42 but this result
may not predict apyrase eﬃcacy against SIPA in severe
stenosis. In addition, the natural platelet inhibitors and nitric
oxide production that endothelial cells provide in vivo are not
present in this model system. These active processes maintain
the quiescent state of platelets while circulating in the body by
scavenging nucleotides released during normal homeostasis
and raising intracellular platelet cyclic-AMP levels.
The open system described in this work is fundamentally
diﬀerent from classical aggregometry experiments. Rather
than an isotropic release throughout the control volume, the
focal nature of the injury necessitates that the ADP generation
is also localized to the growing thrombus site. While laminar
ﬂow is characteristic of physiological conditions found in a
large majority throughout the vasculature, it necessarily is
accompanied by poor radial mixing, especially of non-ionic
molecular species (MW> 100 Da). The competing phenomena
of reaction and convective transport is characterized by a
dimensionless number, typically used to describe chemical
reactor eﬃciency, called the Da¨mkohler number,43,44 deﬁned
by eqn (5).
Da ¼ U  L
V  cA ð5Þ
with ‘U’, ‘L’, ‘V’, and ‘cA’ representing a characteristic reaction
rate, length, velocity, and concentration, respectively. As the
Fig. 3 Representative micrographs of ﬂuorescently labeled platelet
accumulation at the collagen patch. Images are shown at 0 (A), 1 (B),
2 (C), and 5 (D) min of perfusion. Flow is from bottom to top, with
concentrations of MRS 2179 decreasing from left to right in human
whole blood treated with CTI and PPACK. Channels are 250 mm in
width, with reaction zones 250 mm in length. Images are pseudo-
colored in order to increase visibility.
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Da¨mkohler number approaches inﬁnity, the reaction approaches
completion as it would under no-ﬂow conditions (i.e. V - 0)
within the interaction zone. However, as the Da¨mkohler number
approaches zero, convection dominates the system, meaning the
reaction is minimal within the region of interest. In the experi-
mental system and simulation setup, the Da¨mkohler number is
2  103, or close to zero. This is manifested in the fact that
simulation results suggest that exceedingly high apyrase concen-
trations would be required to have an eﬀect on the local ADP
concentration for the given ﬂow proﬁle. It is worthwhile to
reiterate that the experiments and simulations were performed
at a wall shear rate of 210 s1, a relatively low physiological shear
rate. Higher shear rates, and correspondingly higher velocities,
Fig. 4 IC50 curves for three P2-family receptors and apyrase under ﬂow. Representative IC50 curves for MRS 2179 (A, B), 2-MeSAMP (C, D), NF
449 (E, F), and apyrase (G, H), with (A, C, E, G), or without (B, D, F, H) thrombin inhibition. Measurements are shown as points, while the best
ﬁt curve is shown as a solid black line, with the calculated IC50. ‘IC50 = NA’ is shown when no clear dose dependence was displayed.
Table 2 IC50 values for three P2-family receptor antagonists and
apyrase in the presence and absence of thrombin generation capability
(n= 4 diﬀerent donors, p> 0.39 between CTI only and CTI PPACK)
CTI only CTI and PPACK
P2Y1 (MRS 2179) [mM] 0.171  0.093 0.227  0.098
P2Y12 (2-MeSAMP) [mM] 2.619  0.994 2.497  0.700
P2X1 (NF 449) [mM] NA NA
Apyrase (U mL1) NA NA
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would only further decrease the Da¨mkohler number and decrease
the eﬀect of any bulk phase enzymatic-based agonist depletion.
The simple dimensional analysis provided by the Da¨mkohler
number leads to several important clinical implications.
This work indicates that enzyme-mediated ligand removal
for localized surface-mediated events occurring under bulk
convective transport will be limited, not due to enzyme
speciﬁcity, but rather by the time required to react compared
Fig. 5 Results of numerical simulations of apyrase-mediated ADP ﬂux hydrolysis. The well-mixed aggregometer model ((A), eqn (2)–(4)) calculates
the instantaneous ADP concentration for a set of apyrase concentrations in a closed system. (B) Steady-state solutions to the open system (ﬁnite
element method convection-diﬀusion-reaction system with eqn (2) and (3)), with ﬂow depicted from left to right in a 30 mm  400 mm sub-region
(scale bar is 50 mm). The 5 mm zone used to calculate the relevant ADP concentration is outlined in black. (C) Dose response curves of apyrase in
convection-diﬀusion-reaction (red squares) and diﬀusion-reaction (blue circles) systems. The solid lines represent the ﬁt from eqn (1) of the data
used to calculate the IC50.
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to convection away from the zone of interest. A number of
nucleotide phosphohydrolase therapies currently undergoing
testing for diminishing ADP-induced excessive platelet
accumulation in thrombotic pathologies have shown early
success in one of two major ways. The ﬁrst is to use a model
injury system that includes an element of stasis, either an
ischemic stroke model45 or an ischemia/reperfusion thrombosis
model.46 While these in vivo injury model systems are highly
relevant, their intrinsic lack of blood ﬂow at the site of injury
necessarily provides the soluble enzyme the time required to
act, in contrast to injury models in which blood ﬂow is
maintained. The second and newer approach is by which the
enzymatic domain is covalently bound to a targeting moiety,
hence allowing the local enzyme concentration to greatly
increase compared to the bulk concentration at the site of
injury.47 This surface-bound enzyme increases the residence
time of the enzyme at the active site, providing more enzymatic
activity at the site of ADP action.
In summary, this work has shown that a microﬂuidic focal
injury model is capable of measuring the responsiveness of
platelets to a set of inhibitors by measuring changes in
collagen-induced accumulation under ﬂow. While inhibitors
of the P2Y1 and P2Y12 receptors displayed dose-dependent
eﬃcacy, the P2X1 antagonist did not have any eﬀect in this
model system. Similarly, apyrase was not able to reduce
platelet accumulation by hydrolyzing ADP and preventing
its action on subsequent activation of additional platelets.
Numerical simulations have given us insight into why apyrase
is able to function at moderate (1 U mL1) concentrations in
aggregometry and other closed systems, however signiﬁcantly
higher concentrations (2000 U mL1) would be required for
similar abolition of ADP-induced platelet activation under
single-pass ﬂow conditions. In addition, the preferential
hydrolysis of ATP to ADP by a non-speciﬁc apyrase can
increase the local ADP concentration to levels higher than in
the absence of the enzyme, increasing platelet accumulation on
a focal collagen region. This work represents a step towards
what could be a functional assay used to rapidly estimate a
patient’s response to antiplatelet therapy, prior to or during
prophylactic treatment. Additionally, the results of this work
describe the importance of considering method of action and
transport issues relevant to speciﬁc therapeutic goals. Utilizing
computational modeling to help interpret experimental results
and exploring physically unrealizable situations to gain insight
into observed results is shown as a powerful tandem in current
biological systems research. By experimental data informing
computational model inputs and model outputs guiding
subsequent experiments, the complicated and rich interactions
of biology can begin to be understood in ways that can
rely upon the years of extensive research in the engineering
disciplines.
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